LBA Vs. LC-MS: Competing Technologies At A Development Crossroad

The Aliri team recently hosted a webinar exploring why many sponsors are reevaluating the use of Ligand-Binding Assays (LBA) for large molecule protein analysis in favor of Liquid Chromatography-Mass Spectrometry (LC-MS). With its significant advantages in speed, cost efficiency, and data specificity, LC-MS is becoming an increasingly preferred approach in bioanalysis.

In this on-demand webinar, bioanalytical experts Shane Karnik, MS, and Matt Hartle, Ph.D., discuss the evolving market landscape, compare the strengths and limitations of both technologies, and highlight why LC-MS may be the superior choice for your next large molecule program. The session also delves into key advancements in biomarker discovery, validation, and quantification using LC-MS, as well as the challenges of analyzing transgenically expressed proteins — particularly the distinctions between human and endogenous proteins, with a special focus on mRNA-based drugs.

Watch now to gain valuable insights into these critical developments in bioanalysis.